Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 45.15 CHF 0.89% Market Closed
Market Cap: 547.3m CHF

Wall Street
Price Targets

BSLN Price Targets Summary
Basilea Pharmaceutica AG

Wall Street analysts forecast BSLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BSLN is 90.31 CHF with a low forecast of 64.64 CHF and a high forecast of 126 CHF.

Lowest
Price Target
64.64 CHF
43% Upside
Average
Price Target
90.31 CHF
100% Upside
Highest
Price Target
126 CHF
179% Upside
Basilea Pharmaceutica AG Competitors:
Price Targets
688105
Nanjing Vazyme Biotech Co Ltd
15% Upside
MDGL
Madrigal Pharmaceuticals Inc
56% Upside
ACLX
Arcellx Inc
90% Upside
HUMA
Humacyte Inc
337% Upside
KRYS
Krystal Biotech Inc
76% Upside
APGE
Apogee Therapeutics Inc
160% Upside
6160
Beigene Ltd
2% Upside
ELUT
Elutia Inc
410% Upside

Revenue
Forecast

Revenue Estimate
Basilea Pharmaceutica AG

For the last 8 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 15%. The projected CAGR for the next 3 years is 12%.

15%
Past Growth
12%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 3 years is 8%.

N/A
Past Growth
8%
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Net Income
Forecast

Net Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 3 years is 0%.

N/A
Past Growth
0%
Estimated Growth
Estimates Accuracy
-30%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BSLN's stock price target?
Price Target
90.31 CHF

According to Wall Street analysts, the average 1-year price target for BSLN is 90.31 CHF with a low forecast of 64.64 CHF and a high forecast of 126 CHF.

What is Basilea Pharmaceutica AG's Revenue forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 15%. The projected CAGR for the next 3 years is 12%.

What is Basilea Pharmaceutica AG's Operating Income forecast?
Projected CAGR
8%

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 3 years is 8%.

What is Basilea Pharmaceutica AG's Net Income forecast?
Projected CAGR
0%

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 3 years is 0%.

Back to Top